Stocks & Investing
Tue, August 13, 2024
[ Tue, Aug 13th 2024
] - WOPRAI
Fri, August 9, 2024
[ Fri, Aug 09th 2024
] - WOPRAI
Fri, August 2, 2024
[ Fri, Aug 02nd 2024
] - WOPRAI
Fri, May 10, 2024
[ Fri, May 10th 2024
] - WOPRAI
Mon, May 6, 2024
[ Mon, May 06th 2024
] - WOPRAI
Tue, April 30, 2024
[ Tue, Apr 30th 2024
] - WOPRAI
Tue, April 2, 2024
[ Tue, Apr 02nd 2024
] - WOPRAI
Tue, November 14, 2023
[ Tue, Nov 14th 2023
] - WOPRAI
Wed, August 9, 2023
[ Wed, Aug 09th 2023
] - WOPRAI
Fri, June 30, 2023
[ Fri, Jun 30th 2023
] - WOPRAI
Thu, June 22, 2023
[ Thu, Jun 22nd 2023
] - WOPRAI
Fri, June 16, 2023
[ Fri, Jun 16th 2023
] - WOPRAI
Wed, May 10, 2023
[ Wed, May 10th 2023
] - WOPRAI
Fri, May 5, 2023
[ Fri, May 05th 2023
] - WOPRAI
Tue, March 28, 2023
[ Tue, Mar 28th 2023
] - WOPRAI
Fri, March 10, 2023
[ Fri, Mar 10th 2023
] - WOPRAI
Wed, March 1, 2023
[ Wed, Mar 01st 2023
] - WOPRAI
Matthew Caufield Reiterated (ADVM) at Strong Buy and Held Target at $30 on, Aug 13th, 2024
Matthew Caufield of HC Wainwright & Co., Reiterated "Adverum Biotechnologies, Inc." (ADVM) at Strong Buy and Held Target at $30 on, Aug 13th, 2024.
Matthew has made no other calls on ADVM in the last 4 months.
There are 4 other peers that have a rating on ADVM. Out of the 4 peers that are also analyzing ADVM, 0 agree with Matthew's Rating of Hold.
These are the ratings of the 4 analyists that currently disagree with Matthew
- Daniil Gataulin of "Chardan Capital" Maintained at Strong Buy with Increased Target to $40 on, Thursday, July 18th, 2024
- Francois Brisebois of "Oppenheimer" Initiated at Buy and Held Target at $25 on, Tuesday, June 25th, 2024
- Joon Lee of "Truist Securities" Maintained at Strong Buy and Held Target at $60 on, Wednesday, May 15th, 2024
- Graig Suvannavejh of "Mizuho" Maintained at Strong Buy with Decreased Target to $22 on, Monday, April 29th, 2024
